Empire Biotechnologies is a therapeutics company developing best-in-class therapies for diseases with significant unmet medical needs. Our lead asset is an orally delivered protein therapeutic, Mfge8, to treat diseases of inflammation and malabsorption.
the mfge8 solution
Empire Biotechnologies is developing an orally delivered, therapeutic protein (Mfge8) capable of treating inflammation and significantly increasing the absorption of nutrients in the intestine.
Donald McCarthy, PhD
Dr. McCarthy holds a Ph.D. in molecular biology and biochemistry. He is a former postdoctoral fellow in Dr. Atabai’s lab and a leading expert in the space. Dr. McCarthy has previously worked with multiple biotech VC’s and co-founded the biotech equity research firm AMP Biotech Research.
Mr. Mendez graduated with a B.S in Biomedical Engineering from Washington University in St. Louis. He has founded multiple startups and has experience with early stage financing in the healthcare industry.
Ted Daley, MBA
Mr. Daley is a seasoned biotechnology executive with over 10 years of experience in orphan drug development. Most recently, Mr. Daley was President and CBO of Raptor Pharmaceuticals where he helped build the company from a preclinical startup to a publicly traded company.
Kamran Atabai, MD
Dr. Atabai is an Associate Professor of Medicine at UCSF and a foremost expert in mfge8 biology. Dr. Atabai is the inventor of the technology and has published extensively on the subject.
Below you can find publications related to the technology
Interested and want to learn more? Drop us a line.